Avalo Therapeutics Inc
C6K0
Company Profile
Business description
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Contact
540 Gaither Road
Suite 400
RockvilleMD20850
USAT: +1 410 522-8707
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
23
Stocks News & Analysis
stocks
Chart of the Week: Aussie dividend yields are less attractive than alternatives
The latest insights from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.70 | 32.60 | 0.37% |
| CAC 40 | 8,110.29 | 24.24 | 0.30% |
| DAX 40 | 23,998.32 | 37.73 | 0.16% |
| Dow JONES (US) | 47,885.97 | 228.29 | -0.47% |
| FTSE 100 | 9,792.59 | 18.27 | 0.19% |
| HKSE | 25,498.13 | 29.35 | 0.12% |
| NASDAQ | 22,693.32 | 418.14 | -1.81% |
| Nikkei 225 | 49,001.50 | 510.78 | -1.03% |
| NZX 50 Index | 13,256.77 | 39.14 | -0.29% |
| S&P 500 | 6,721.43 | 78.83 | -1.16% |
| S&P/ASX 200 | 8,588.20 | 31.70 | 0.37% |
| SSE Composite Index | 3,876.37 | 6.09 | 0.16% |